Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CBSCOTCMKTS:PVOTFNASDAQ:QTTBNYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBSCCB Scientific$0.05+12.3%$0.04$0.02▼$0.15$8.22M1.1967,506 shs126,000 shsPVOTFBetterLife Pharma$0.00$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsQTTBQ32 Bio$1.62-1.8%$1.76$1.38▼$53.79$19.76M-0.02196,256 shs63,082 shsVORVor Biopharma$0.18-5.5%$0.56$0.13▼$1.80$22.07M-0.21977,323 shs1.53 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBSCCB Scientific+12.30%+48.08%+26.45%-22.77%-37.25%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%QTTBQ32 Bio-1.82%-8.47%-14.74%-36.96%-94.56%VORVor Biopharma-5.46%-0.17%-76.74%-87.11%-89.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBSCCB ScientificN/AN/AN/AN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/AQTTBQ32 Bio2.2682 of 5 stars3.14.00.00.00.61.71.3VORVor Biopharma2.3782 of 5 stars4.20.00.00.01.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBSCCB Scientific 0.00N/AN/AN/APVOTFBetterLife Pharma 0.00N/AN/AN/AQTTBQ32 Bio 2.25Hold$24.711,425.57% UpsideVORVor Biopharma 2.40Hold$7.063,896.12% UpsideCurrent Analyst Ratings BreakdownLatest CBSC, VOR, PVOTF, and QTTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025VORVor BiopharmaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025VORVor BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform$6.00 ➝ $6.005/9/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/8/2025VORVor BiopharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2025VORVor BiopharmaBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$7.00 ➝ $0.403/21/2025VORVor BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/21/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.50 ➝ $13.003/21/2025VORVor BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $5.003/20/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$7.003/12/2025QTTBQ32 BioWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBSCCB Scientific$140K58.69N/AN/AN/A∞PVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/AQTTBQ32 Bio-$6.65M-2.97N/AN/A$22.47 per share0.07VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBSCCB ScientificN/AN/A0.00∞N/AN/AN/AN/AN/APVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/AQTTBQ32 Bio-$112.96M-$4.94N/AN/AN/AN/A-146.18%-54.49%N/AVORVor BiopharmaN/A-$1.51N/AN/AN/AN/AN/AN/AN/ALatest CBSC, VOR, PVOTF, and QTTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025QTTBQ32 Bio-$1.23-$0.90+$0.33-$0.90N/AN/A3/11/2025Q4 2024QTTBQ32 Bio-$1.25-$1.16+$0.09-$1.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBSCCB ScientificN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBSCCB ScientificN/AN/AN/APVOTFBetterLife PharmaN/A3.623.62QTTBQ32 Bio0.616.536.53VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBSCCB ScientificN/APVOTFBetterLife PharmaN/AQTTBQ32 Bio31.32%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipCBSCCB ScientificN/APVOTFBetterLife Pharma34.77%QTTBQ32 Bio40.00%VORVor Biopharma2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBSCCB Scientific5163.67 millionN/ANot OptionablePVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionableQTTBQ32 Bio3912.20 million10.22 millionN/AVORVor Biopharma140124.96 million65.45 millionNot OptionableCBSC, VOR, PVOTF, and QTTB HeadlinesRecent News About These CompaniesVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Hold" by AnalystsMay 16, 2025 | americanbankingnews.comRA Capital's biotech incubator lays off staffers: StatMay 15, 2025 | fiercebiotech.comStifel cuts Vor Biopharma stock rating amid clinical and financial concernsMay 10, 2025 | investing.comJMP Securities Downgrades Vor Biopharma (VOR)May 10, 2025 | msn.comVor Biopharma draws downgrades on strategic reviewMay 9, 2025 | msn.comJones Trading cuts Vor Biopharma stock rating to HoldMay 9, 2025 | investing.comHC Wainwright & Co. Downgrades Vor Biopharma (VOR)May 9, 2025 | msn.com4 more biotechs cut staff amid market tumultMay 9, 2025 | biopharmadive.comBlood cancer biotech Vor Bio ends clinical work, lays off 95% of staffMay 8, 2025 | endpts.comVor Bio Winding Down Operations, Cutting Workforce, Exploring Potential SaleMay 8, 2025 | marketwatch.comVor Biopharma: Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueMay 8, 2025 | finanznachrichten.deVor Biopharma stock plummets on operation wind-downMay 8, 2025 | in.investing.comVor Bio to wind down, halting cell therapy trials and shedding most staffMay 8, 2025 | fiercebiotech.comVor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueMay 8, 2025 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Shares Bought by RA Capital Management L.P.May 3, 2025 | marketbeat.comLynx1 Capital Management LP Buys New Stake in Vor Biopharma Inc. (NYSE:VOR)April 29, 2025 | marketbeat.comVor Biopharma faces Nasdaq delisting over low stock priceApril 27, 2025 | investing.comVor Bio price target lowered to $5 from $12 at StifelMarch 22, 2025 | markets.businessinsider.comVor Bio price target lowered to $13 from $17.50 at H.C. WainwrightMarch 22, 2025 | markets.businessinsider.comVor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company UpdateMarch 21, 2025 | finanznachrichten.deVor Bio files $350M mixed securities shelfMarch 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBig Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025By Nathan Reiff | May 15, 2025View Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryBy Jeffrey Neal Johnson | April 27, 2025View Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryShort Sellers Gave Up on These 3 Names RecentlyBy Gabriel Osorio-Mazilli | April 25, 2025View Short Sellers Gave Up on These 3 Names RecentlyRetail Investors Are Betting Big on Rocket Lab—Should You Too?By Ryan Hasson | May 16, 2025View Retail Investors Are Betting Big on Rocket Lab—Should You Too?Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond?By Thomas Hughes | May 22, 2025View Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond?CBSC, VOR, PVOTF, and QTTB Company DescriptionsCB Scientific OTCMKTS:CBSC$0.05 +0.01 (+12.30%) As of 05/23/2025 03:41 PM EasternCB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.BetterLife Pharma OTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.Q32 Bio NASDAQ:QTTB$1.62 -0.03 (-1.82%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.64 +0.02 (+1.48%) As of 05/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Vor Biopharma NYSE:VOR$0.18 -0.01 (-5.46%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.18 +0.01 (+3.06%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
